Introduction
============

Cancer is a leading cause of morbidity and mortality, with approximately 14 million new cases diagnosed and 8 million cancer-related deaths worldwide in 2012 \[[@b1-yujm-2019-00451]\]. The three major gynecologic cancers are cervical, endometrial, and ovarian cancer. Cervical cancer is the 4th most common malignancy in women worldwide and the disease resulted in over 300,000 deaths in 2018 \[[@b2-yujm-2019-00451]\]. High-risk subtypes of the human papilloma virus (HPV) are the cause for most cervical cancers, and HPV screening and vaccination programs are effective for disease prevention. Endometrial cancer is the most common gynecologic malignancy in developed countries, with a rising incidence. In 2012, around 320,000 new cases of endometrial cancer were diagnosed worldwide \[[@b3-yujm-2019-00451]\]. Ovarian cancer is the common cause of gynecological cancer associated with death. One of the reasons for high mortality is late presentation in most cases. This cancer usually presents in postmenopausal women without typical symptoms. In 2018, about 295,000 new cases of ovarian cancer were diagnosed worldwide \[[@b4-yujm-2019-00451]\]. Based on the characteristics of gynecological cancers discussed above, the purpose of this study is to review the clinico-pathologic characteristics of patients with gynecological cancers treated at our hospital.

Materials and methods
=====================

We retrospectively identified patients with invasive gynecological cancers who were treated at Yeungnam University Medical Center from January 1, 2012 to February 28, 2019. This study was approved by the Institutional Review Board of the Yeungnam University Medical Center (IRB No: 2019-11-004). The disease codes used were according to the International Classification of Diseases, 10th edition, which included cervical cancer (C53), uterine corpus cancer (C54, C55), ovarian cancer (C56), tubal cancer (C57), and primary peritoneal cancer (C48). Cervical carcinoma in situ, borderline ovarian malignancy, vaginal cancer, and choriocarcinoma were excluded from the study. Patients who were transferred to other hospitals immediately after diagnosis were also excluded. Finally, 287 cases of gynecological cancer were included in this study. We analyzed the clinical features, demographic profiles, pathologic data, treatment modality used, adjuvant treatment used, complications, recurrence, progression-free survival (PFS), and overall survival (OS) of all patients. All cases were pathologically confirmed as gynecological cancer; however, a few cases of ovarian cancer were clinically diagnosed when cytological and imaging studies strongly suggested ovarian cancer. At our hospital, the baseline investigations for cervical cancer usually include serum squamous cell cancer-antigen (SCC-Ag) level, chest X-ray, cystoscopy, sigmoidoscopy, pelvic magnetic resonance imaging (MRI), and positron emission tomography-computed tomography (PET-CT). For endometrial cancer, the baseline investigations include serum cancer antigen-125 (CA-125) level, chest X-ray, sigmoidoscopy, pelvic MRI, and PET-CT. For ovarian cancer, the initial work-up includes the risk of ovarian malignancy algorithm (ROMA) test, chest X-ray, gastroscopy, colonoscopy, pelvic CT, and PET-CT. The stages of cervical and corporal cancer were classified according to the International Federation of Gynecology and Obstetrics (FIGO) classification 2009, and ovarian cancer was classified according to the FIGO stage 2014.

PFS was determined from the date of diagnosis to the date of first recurrence or the date of last follow-up. OS was determined from the date of diagnosis to the date of death or the date of last follow-up. Statistical analyses were performed using the IBM SPSS version 20.0 (IBM Corp., Armonk, NY, USA). Survival analyses were conducted using the Kaplan-Meier method, and surviving patients were censored at the date of last follow-up.

Results
=======

1. Cervical cancer
------------------

Demographic characteristics and clinical features of patients with cervical cancer (n=115) are described in [Table 1](#t1-yujm-2019-00451){ref-type="table"}. The mean age at diagnosis was 53.8 years. The most common presenting symptom was vaginal bleeding, seen in 55 patients (47.8%). Forty-seven patients (40.9%) were diagnosed with cervical cancer during routine health screening. More than half of the patients (67.0%) were diagnosed at stage I, while 15.7% were diagnosed at stage II. Serum SCC-Ag test was performed in 81 patients, and 43 of them (53.1%) had abnormal results (\>1.5 ng/mL). The mean SCC-Ag level was 5.5 ng/mL at diagnosis. The most frequent histological type was squamous cell carcinoma (74.8%). Adenocarcinomas and adenosquamous carcinomas were found in 18.3% and 1.7% of the cases respectively. Fifty-two patients (45.2%) underwent only surgery while 26 patients (22.6%) received concurrent chemoradiation therapy as front-line therapy. Most patients (96.2%) treated with chemoradiotherapy received cisplatin alone. The most common surgical modality was open surgery (35 cases, 30.4%), followed by laparoscopic surgery (31 cases, 27.0%). Surgical complications occurred in 14 patients including bladder dysfunction in five patients, pelvic abscess in two patients, wound dehiscence in two patients, and deep vein thrombosis, sciatic neuropathy, vaginal vault bleeding, ureter injury and postoperative sepsis in one patient each. During the 32 months of median follow-up period, there were 17 cases with recurrence and seven deaths. Five-year PFS was 81.0%, and 5-year OS was 94.1%. Median PFS and OS were not reached. PFS and OS for each cancer site are shown in [Fig. 1](#f1-yujm-2019-00451){ref-type="fig"}.

2. Uterine corpus cancer
------------------------

Demographic characteristics and clinical features (n=86) are described in [Table 2](#t2-yujm-2019-00451){ref-type="table"}. The mean age at diagnosis was 56.9 years. The most common presenting symptom was vaginal bleeding, in 66 patients (76.7%). Nine patients (10.5%) were diagnosed during routine health screening. Most cases (83.7%) were in stage I at diagnosis and 9.3% of the cases were in stage III. Mean serum CA-125 level was 59.5 U/mL at diagnosis. The most frequent histological type was endometrioid carcinoma (69.8%), followed by serous carcinomas (7.0%) and carcinosarcoma (7.0%). Leiomyosarcoma and endometrial stromal sarcoma were diagnosed in 4.7% and 2.3% of the cases respectively. Forty-five patients (52.3%) underwent only surgery. A case in stage IA underwent dilatation and curettage followed by adjuvant hormonal therapy using levonorgestrel-releasing intrauterine device for preservation of fertility. Following surgery, 21 patients (24.4%) received adjuvant chemotherapy, 16 patients (18.6%) received radiotherapy and two patients (2.3%) received adjuvant chemoradiation. Almost half of the patients (47.6%) were treated with adjuvant chemotherapy using paclitaxel and carboplatin, and the rest with cisplatin-based combined regimen. The most common surgical modality was open surgery (45 cases, 52.3%), followed by laparoscopic surgery (36 cases, 41.9%). The following surgical complications were observed: wound dehiscence in six patients, infection at the drainage site in two patients, and ureteral injury, bladder injury, vaginal wall laceration, small bowel injury, voiding difficulty and intracranial hemorrhage in one patient each. During the 28 months of median follow-up, there were 16 cases with recurrence and seven deaths. The 5-year PFS was 79.3%, and 5-year OS was 91.0%. Median PFS and OS were not reached.

3. Ovarian, tubal and primary peritoneal cancer
-----------------------------------------------

Pathologic characteristics and clinical features of patients with ovarian, tubal and peritoneal cancer (n=90) are described in [Table 3](#t3-yujm-2019-00451){ref-type="table"}. The mean age was 56.3 years. The predominant presenting symptoms were abdominal pain (34.4%), abdominal distension (22.2%), vaginal bleeding (12.2%), and palpable pelvic mass (10.0%). Cases of incidental diagnosis were 14.4%. Serum CA-125 test was conducted in 83 out of 90 patients, and 60 of them (72.3%) had abnormal results (\>35 U/mL). The mean CA-125 level was 727.6 U/mL at diagnosis. In our hospital, Breast Cancer Susceptibility Gene (BRCA) mutation test was initiated at the department of gynecology in February 2016 on a whole blood sample using polymerase chain reaction and direct sequencing. In all, 18 patients with ovarian, tubal, or peritoneal cancer underwent the test, and 4 (22.2%) were positive: BRCA1 and BRCA2 were positive in two patients each. The site of primary cancer was ovaries in 87.8%, fallopian tubes in 3.3%, and peritoneum in 5.6%. More than half the patients (58.9%) were in the advanced stage (stage III or IV) at diagnosis. The most common epithelial histological type was serous adenocarcinoma (53.3%) while mucinous carcinoma and clear cell carcinoma were found in 10.0% each. Twenty patients (22.2%) underwent only surgery, while 54 patients (60.0%) received postoperative adjuvant chemotherapy. Ten patients (11.1%) underwent surgery after neoadjuvant chemotherapy. Paclitaxel plus carboplatin was used in 90.0% of the neoadjuvant chemotherapy regimens and cyclophosphamide plus cisplatin was used in the remaining 10.0%. Bevacizumab has been introduced in January 2015 in our hospital and has been used in 11 patients. The most common surgical modality was open surgery (67 cases, 74.4%), followed by laparoscopic surgery (16 cases, 17.8%). Five patients (5.5%) underwent fertility preserving surgery. The following surgical complications were observed: wound dehiscence in five patients, and bowel leak, bladder injury, deep vein thrombosis, acute kidney injury and cerebral infarction in one patient each. During the 23 months of median follow-up, there were 34 recurrences and 19 deaths. The 5-year PFS was 62.0%, and 5-year OS was 77.1%. Median PFS was 43 months (95% confidence interval, 20.5--65.5), and median OS was not reached.

Discussion
==========

Cervical cancer is the most common gynecological cancer in developing countries while endometrial cancer is the most common gynecological cancer in developed countries. The incidence of ovarian cancer is also higher in developed countries than in developing countries. In line with this trend, the incidence of cervical cancer is gradually decreasing, while that of uterine corporal and ovarian cancers is increasing in Korea. Our data showed the overall clinico-pathologic results in patients who were treated for major gynecological cancers at our hospital. Limitations of the present study include its retrospective design, small sample size, and single-group analysis without comparison of data from other institutions. Nevertheless, this review of our data presents an opportunity to understand the characteristics of local population with gynecological malignancies and to evaluate the outcomes of our management.

The incidence and mortality of cervical cancer have decreased since the introduction of screening programs. Furthermore, in countries where HPV vaccination program has been introduced, a substantial decrease in the incidence of cervical cancer is expected. According to the 2015 annual report of cancer statistics in Korea, the incidence of cervical cancer was high in the age groups of 40s, 50s and 30s \[[@b5-yujm-2019-00451]\]. Similarly, our data showed that the incidence was highest with 29.6% in the 50s, followed by 21.7% in the 40s, and 17.4% in the 30s. The Surveillance, Epidemiology, and End Results (SEER) data in the United States reported the incidence of cervical cancer diagnosed in different stages as follows: 44% for localized disease, 36% for regional disease, and 15% for distant disease \[[@b6-yujm-2019-00451]\]. The incidence of different stages of cancer in our data was slightly different: 67.0% localized disease, 21.7% regional disease, and 11.3% distant disease. Such a high proportion of localized disease seems to be due to active national cervical cancer screening. Globally, squamous cell carcinoma and adenocarcinoma are the most common histological subtypes accounting for approximately 70% and 25% of all cervical cancers, respectively \[[@b2-yujm-2019-00451]\]. The histological analysis of cervical cancer patients in our hospital showed 74.8% to be squamous cell carcinoma, 18.3% adenocarcinoma, and 1.7% adenosquamous cell carcinoma, which is in line with the global trend. According to the SEER data, the 5-year survival rate was 65.5% in 2015 \[[@b6-yujm-2019-00451]\], while the 5-year survival rate in the patients in our study was 94.1%. There might be various factors related to the difference in survival rates such as ethnic, racial, sociocultural, and other demographic characteristics, as well as the national medical policy and program. In addition, a better survival rate could be partially because our study included more cases in the early stage of the disease as follows: 25 cases (21.7%) in stage IA1, 5 cases (4.3%) in IA2, 36 cases (31.3%) in stage IB1, and 11 cases (9.6%) in stage IB2. The surgical treatment appeared to be generally tolerable in terms of the incidence (12.2%) and severity of complications.

In endometrial cancer, the most common histologic type is endometrioid adenocarcinoma (80%), while the other types are mucinous carcinoma (5%), papillary serous carcinoma (3%--4%), and clear cell carcinoma (\<5%) \[[@b7-yujm-2019-00451]\]. The standard treatment for early-stage endometrial cancer is surgery including total hysterectomy and bilateral salpingo-oophorectomy. The safety and advantages of laparoscopic surgery have been proven in several randomized clinical trials \[[@b8-yujm-2019-00451],[@b9-yujm-2019-00451]\]. In our data, the rate of laparoscopic surgery was quite high (41.8%). According to the SEER data, the 5-year survival rate was 81.0% in 2015, while the 5-year survival rate in the patients in our study was 91.0% \[[@b10-yujm-2019-00451]\].

BRCA 1/2 mutations are the most frequently identified genetic changes associated with ovarian cancer. It has been recently known that a BRCA 1/2 germline mutation is associated with poor prognostic factors such as early-onset cancer, serous histology, and advanced stages of cancer \[[@b11-yujm-2019-00451]\]. The incidence of BRCA 1/2 mutations has been reported to be 16.5% in the ovarian cancer patients in Korea \[[@b12-yujm-2019-00451]\]. In our data, BRCA 1/2 mutation was seen in 22.2% of the patients with ovarian cancer, which is probably due to the small sample size in the present study. In addition, clear cell carcinoma was found in a high proportion (10.0%) of ovarian cancer patients. In general, clear cell carcinoma accounts for about 5% of all ovarian cancers \[[@b13-yujm-2019-00451]\]. According to the SEER data, the 5-year survival rate was 47.8% in 2015, while the 5-year survival rate in the patients in our study was 77.1% \[[@b14-yujm-2019-00451]\]. More cases detected at an early stage might be a reason for the better survival. The distribution of various stages of cancer was as follows: localized malignancy and distant metastasis 15% and 59% respectively in the SEER data and 36.7% and 21.1% respectively in our data.

In summary, most characteristics were similar with those of the worldwide data. The survival outcomes of patients with gynecological cancer in our data were generally good. Clinicians should well be aware of the clinical and histopathological characteristics of the patients with gynecological cancer to be able to provide optimal management options.

**Conflicts of interest**

No potential conflict of interest relevant to this article was reported.

**Author contributions**

Conceptualization: YJK; Data curation: SYL, EK, HSK; Formal analysis: SYL, YJK; Methodology: YJK; Project administration: DHL; Software: YJK; Supervision: YJK, DHL; Writing-original draft: SYL; Writing-review & editing: YJK.

![Progression-free survival (A) and overall survival (B) of the patients by the cancer sites.](yujm-2019-00451f1){#f1-yujm-2019-00451}

###### 

Clinical and histopathologic characteristics of the uterine cervical cancers (n=115)

  Clinicopathologic characteristic                                    Value
  ------------------------------------------------------------------- ---------------
  Age (yr)                                                            53.8 (31--86)
  Symptom                                                             
   Vaginal bleeding                                                   55 (47.8)
   Incidentally detected on routine health screening                  47 (40.9)
   Abdominal pain                                                     6 (5.2)
   Vaginal discharge                                                  5 (4.3)
   Others^[a)](#tfn2-yujm-2019-00451){ref-type="table-fn"}^           2 (1.7)
  Gravidity (no. of times)                                            4.0 (0--30)
  Parity (no. of times)                                               2.3 (0--9)
  Body mass index (kg/m^2^)                                           23.2 (15--34)
  History of non-gynecologic malignancy                               11 (9.6)
  Serum SCC-Ag at diagnosis (ng/mL)                                   5.5 (0.2--70)
  Tumor size^[b)](#tfn3-yujm-2019-00451){ref-type="table-fn"}^ (cm)   3.1 (0.1--21)
  Synchronous primary cervical and endometrial cancers                1 (0.9)
  Histology type                                                      
   Squamous cell carcinoma                                            86 (74.8)
   Adenocarcinoma                                                     21 (18.3)
   Adenosquamous carcinoma                                            2 (1.7)
   Others^[c)](#tfn4-yujm-2019-00451){ref-type="table-fn"}^           6 (5.2)
  FIGO stage                                                          
   I                                                                  77 (67.0)
   II                                                                 18 (15.7)
   III                                                                7 (6.1)
   IV                                                                 13 (11.3)
  Initial treatment                                                   
   Surgery alone                                                      52 (45.2)
   Concurrent chemoradiation                                          26 (22.6)
   Surgery+radiotherapy                                               11 (9.6)
   Radiotherapy alone                                                 8 (7.0)
   Surgery+concurrent chemoradiation                                  7 (6.1)
   Surgery+adjuvant chemotherapy                                      4 (3.5)
   Neoadjuvant chemotherapy+surgery±any adjuvant therapy              5 (4.3)
   Others                                                             2 (1.7)
  Surgical mode                                                       
   Abdominal                                                          35 (30.4)
   Laparoscopic                                                       31 (27.0)
   Robotic                                                            4 (3.5)
   Vaginal (wide conization)                                          12 (10.4)
  Hysterectomy procedures                                             
   Extrafascial hysterectomy                                          24 (20.9)
   Modified radical hysterectomy                                      9 (7.8)
   Radical hysterectomy                                               37 (32.2)
  Pelvic lymphadenectomy                                              50 (43.5)
  Paraaortic lymphadenectomy                                          21 (18.3)
  Surgical complications                                              14 (12.2)
  Recurrence or progression                                           17 (14.8)
  Death                                                               7 (6.1)

Values are presented as number (%) or mean (range).

SCC-Ag, serum squamous cell cancer-antigen; FIGO, International Federation of Gynecology and Obstetrics.

Abdominal distension in one; headache in one case.

Maximal diameter of the tumor either on the initial imaging study or on the pathologic finding.

Mucinous carcinoma in two; diffuse large B-cell lymphoma in one; neuroendocrine carcinoma in one; adenosarcoma in one; mixed carcinoma in one case.

###### 

Clinical and histopathologic characteristics of the uterine corpus cancers (n=86)

  Clinicopathologic characteristic                                    Value
  ------------------------------------------------------------------- -------------------
  Age (yr)                                                            56.9 (29--85)
  Symptom                                                             
   Vaginal bleeding                                                   66 (76.7)
   Incidentally detected on routine health screening                  9 (10.5)
   Abdominal pain                                                     4 (4.7)
   Abdominal distension                                               4 (4.7)
   Palpable pelvic mass                                               3 (3.5)
   Vaginal discharge                                                  2 (2.3)
  Gravidity (no. of times)                                            3.7 (0--21)
  Parity (no. of times)                                               2.1 (0--7)
  Body mass index (kg/m^2^)                                           25.3 (17.1--38.9)
  History of non-gynecologic malignancy                               13 (15.1)
  Serum CA-125 level at diagnosis (U/mL)                              59.5 (1.1--1,220)
  Tumor size^[a)](#tfn6-yujm-2019-00451){ref-type="table-fn"}^ (cm)   4.1 (0.2--20)
  Synchronous primary endometrial and ovarian cancers                 3 (3.5)
  Histologic type                                                     
   Endometrioid carcinoma                                             60 (69.8)
   Serous carcinoma                                                   6 (7.0)
   Carcinosarcoma                                                     6 (7.0)
   Leiomyosarcoma                                                     4 (4.7)
   Endometrial stromal sarcoma                                        2 (2.3)
   Others^[b)](#tfn7-yujm-2019-00451){ref-type="table-fn"}^           8 (9.3)
  Histologic grade in case of endometrioid carcinoma                  
   1                                                                  30 (34.9)
   2                                                                  24 (27.9)
   3                                                                  6 (7)
  FIGO stage                                                          
   I                                                                  72 (83.7)
   II                                                                 5 (5.8)
   III                                                                8 (9.3)
   IV                                                                 1 (1.2)
  Initial treatment                                                   
   Surgery alone                                                      45 (52.3)
   Surgery+adjuvant chemotherapy                                      21 (24.4)
   Surgery+radiotherapy                                               16 (18.6)
   Surgery+chemoradiation                                             2 (2.3)
   Surgery+hormone therapy                                            2 (2.3)
  Surgical mode                                                       
   Abdominal                                                          45 (52.3)
   Laparoscopic                                                       36 (41.9)
   Robotic                                                            4 (4.7)
   Vaginal (dilatation and curettage)                                 1 (1.2)
  Pelvic lymphadenectomy                                              53 (61.6)
  Paraaortic lymphadenectomy                                          36 (41.9)
  Surgical complications                                              14 (16.3)
  Recurrence or progression                                           16 (18.6)
  Death                                                               7 (8.1)

Values are presented as numbers (%) or means (range).

CA-125, cancer antigen-125; FIGO, International Federation of Gynecology and Obstetrics.

Maximal diameter of the tumor either on the initial imaging study or on the pathologic finding.

Mixed carcinoma in four; mucinous carcinoma in two; undifferentiated carcinoma in one; Mullerian adenosarcoma in one.

###### 

Clinical and histopathologic characteristics of the ovarian, tubal, and primary peritoneal cancers (n=90)

  Clinicopathologic characteristic                                    Value
  ------------------------------------------------------------------- ----------------------
  Age (yr)                                                            56.3 (13--80)
  Symptom                                                             
   Abdominal pain                                                     31 (34.4)
   Abdominal distension                                               20 (22.2)
   Incidentally detected on routine health screening                  13 (14.4)
   Vaginal bleeding                                                   11 (12.2)
   Palpable pelvic mass                                               9 (10.0)
   Others                                                             7 (7.8)
  Gravidity (no. of times)                                            2.8 (0--8)
  Parity (no. of times)                                               1.7 (0--6)
  Body mass index (kg/m^2^)                                           22.8 (15.9--30)
  History of non-gynecologic malignancy                               13 (14.4)
  Serum CA-125 level at diagnosis (U/mL)                              727.6 (0.1--7,187.9)
  Tumor size^[a)](#tfn9-yujm-2019-00451){ref-type="table-fn"}^ (cm)   9.6 (0.5--25)
  Primary cancer site                                                 
   Ovary                                                              79 (87.8)
   Synchronous primary endometrial and ovarian cancers                3 (3.3)
   Fallopian tube                                                     3 (3.3)
   Peritoneum                                                         5 (5.6)
  Histologic type                                                     
   Serous                                                             48 (53.3)
   Mucinous                                                           9 (10.0)
   Clear cell                                                         9 (10.0)
   Endometrioid                                                       8 (8.9)
   Others^[b)](#tfn10-yujm-2019-00451){ref-type="table-fn"}^          10 (11.1)
   Unknown^[c)](#tfn11-yujm-2019-00451){ref-type="table-fn"}^         6 (6.7)
  Histologic grade in case of serous carcinoma                        
   Low-grade                                                          2 (2.2)
   High-grade                                                         45 (50)
   Unknown                                                            1 (1.1)
  FIGO stage                                                          
   I                                                                  33 (36.7)
   II                                                                 4 (4.4)
   III                                                                34 (37.8)
   IV                                                                 19 (21.1)
  Initial treatment                                                   
   Surgery alone                                                      20 (22.2)
   Surgery+adjuvant chemotherapy                                      54 (60.0)
   Neoadjuvant chemotherapy+surgery+adjuvant chemotherapy             9 (10.0)
   Neoadjuvant chemotherapy+surgery                                   1 (1.1)
   Palliative chemotherapy                                            5 (5.6)
   Supportive care alone                                              1 (1.1)
  Surgical mode                                                       
   Abdominal                                                          67 (74.4)
   Laparoscopic                                                       16 (17.8)
   Robotic                                                            1 (1.1)
  Fertility-sparing surgery                                           
   Unilateral salpingo-oophorectomy                                   4 (4.4)
   Ovarian cystectomy                                                 1 (1.1)
  Postoperative residual tumor                                        
   Grossly none                                                       52 (57.8)
   Size \<2 cm                                                        9 (10.0)
   Size ≥2 cm                                                         23 (25.6)
  Pelvic lymphadenectomy                                              49 (54.4)
  Paraaortic lymphadenectomy                                          43 (47.8)
  Surgical complications                                              10 (11.1)
  Recurrence or progression                                           34 (37.8)
  Death                                                               19 (21.1)

Values are presented as numbers (%) or means (range).

CA-125, cancer antigen-125; FIGO, International Federation of Gynecology and Obstetrics.

Maximal diameter of the tumor either on the initial imaging study or on the pathologic finding.

Adenocarcinoma in two; immature teratoma in two; adult granulosa cell tumor in one; transitional cell carcinoma in one; small cell carcinoma in one; undifferentiated carcinoma in one; dysgerminoma in one; poorly differentiated carcinoma in one case.

Clinically diagnosed by both ascites cytology and imaging studies.
